| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| BRISTOL MYERS SQUIBB CO | SVP,Head Glob. Medical Affairs | Common Stock, $0.10 par value | 9.49K | $472K | $49.78 | Jun 3, 2021 | Direct |
| BRISTOL MYERS SQUIBB CO | SVP,Head Glob. Medical Affairs | Restricted Stock Units | 4.31K | $216K | $50.10 | Jun 3, 2021 | Direct |
| GERON CORP | EVP, Research and Development | Stock Option (right to buy) | 2.5M | Nov 11, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| GERN | GERON CORP | Nov 11, 2024 | 0 | $0 | 3 | Nov 12, 2024 | EVP, Research and Development |
| GERN | GERON CORP | Nov 11, 2024 | 1 | $0 | 4 | Nov 12, 2024 | EVP, Research and Development |
| BMY | BRISTOL MYERS SQUIBB CO | Jun 3, 2021 | 3 | -$47.8K | 4 | Jun 4, 2021 | SVP,Head Glob. Medical Affairs |
| BMY | BRISTOL MYERS SQUIBB CO | May 10, 2021 | 1 | -$72.7K | 4 | May 11, 2021 | SVP,Head Glob. Medical Affairs |